• Neurocrine Biosciences Chief Commercial Officer Eric Benevich sold 2,154 shares of common stock on Sept. 9, 2026 at USD 154.61.
• He exercised an incentive stock option for 3,194 shares the same day at USD 43.24.
• Holdings stood at 64,408 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001643653-26-000016), on September 10, 2026, and is solely responsible for the information contained therein.